Close Menu

NEW YORK (GenomeWeb) – Luminex announced today that it has received US Food and Drug Administration approval for its Aries Group B Streptococcus (GBS) assay for antepartum detection of GBS colonization in pregnant women.

The test runs on Luminex's real-time PCR-based sample-to-answer Aries system and is designed to detect GBS nucleic acid from 18 to 24 hour Lim broth enriched vaginal-rectal swab specimens obtained from pregnant women.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.